Coenzyme Q10 as Adjunctive Therapy in Drug-Resistant Epilepsy (NCT07537283) | Clinical Trial Compass
CompletedNot Applicable
Coenzyme Q10 as Adjunctive Therapy in Drug-Resistant Epilepsy
Taiwan39 participantsStarted 2023-02-07
Plain-language summary
This study evaluates the efficacy and safety of coenzyme Q10 supplementation as adjunctive therapy in patients with drug-resistant epilepsy.
Who can participate
Age range20 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 20 to 80 years.
* Diagnosed with drug-resistant epilepsy.
* Receiving stable anti-seizure medications for at least 4 weeks prior to enrollment.
* Able to provide informed consent.
* Willing and able to maintain seizure diaries throughout the study period.
Exclusion Criteria:
* History of progressive neurological disease.
* Severe systemic illness (e.g., uncontrolled cardiovascular, hepatic, or renal disease).
* Use of coenzyme Q10 or other mitochondrial supplements within 4 weeks prior to enrollment.
* Pregnancy or breastfeeding.
* Known allergy or hypersensitivity to coenzyme Q10.
* Participation in another clinical trial within the past 3 months.